ChitogenX Inc. (CHNXF)
ChitogenX Inc.
16667 Hymus Boulevard
Kirkland, QC H9H 4R9
Canada
514-261-4735
https://www.chitogenx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Pierre Laurin B.Sc.Pharm., M.Sc. | Interim CEO & Chairman | N/D | N/D | 1961 |
| Mr. Luc Mainville M.B.A, M.B.A. | Senior VP & CFO | 136.56k | N/D | 1964 |
| Mr. Guy-Paul Allard | VP of Legal Affairs & Corporate Secretary | N/D | N/D | N/D |
| Dr. Jonathan Sackier | Senior Vice President of Medical Affairs | 204.48k | N/D | N/D |
| Mr. Frederic Dumais | Director of Communications & Investor Relations | N/D | N/D | N/D |
| Benedek Simo | Controller | N/D | N/D | N/D |
Descripción
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de ChitogenX Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
